Anzeige
Mehr »
Donnerstag, 18.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40GN1 | ISIN: CA4229102088 | Ticker-Symbol: HBP0
Frankfurt
18.09.25 | 08:04
0,890 Euro
+2,30 % +0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HELIX BIOPHARMA CORP Chart 1 Jahr
5-Tage-Chart
HELIX BIOPHARMA CORP 5-Tage-Chart

Aktuelle News zur HELIX BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.09.Helix BioPharma Corp.: Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025212TORONTO, ON / ACCESS Newswire / September 9, 2025 / Helix BioPharma Corp. (TSX:HBP)(OTC:HBPCF)(FRANKFURT:HBP0) ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where...
► Artikel lesen
06.09.Helix BioPharma Corp (2): Helix ends review, drops GEM equity facility plan7
05.09.Helix BioPharma Corp.: Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM2
23.08.Helix BioPharma Corp.: Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting3
23.08.Helix BioPharma Corp (2): Helix BioPharma closes $1.66-million private placement2
14.08.Helix BioPharma Corp (2): Helix publishes article in Frontiers in Oncology5
HELIX BIOPHARMA Aktie jetzt für 0€ handeln
13.08.Helix BioPharma Corp.: Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC3
17.06.Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 20251
03.06.Helix BioPharma Corp (2): Helix BioPharma appoints Babbar as CFO4
02.06.Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones2
21.05.Helix BioPharma Corp (2): Helix BioPharma closes acquisitions of Laevoroc assets3
20.05.Helix BioPharma Corp.: Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA and GEMCEDA in Strategic Acquisition from the Laevoroc Group1
15.05.Helix BioPharma Corp (2): Helix BioPharma signs capital raising agreement3
14.05.Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.1
25.04.Helix BioPharma Corp (2): Helix Bio appoints Kandziora, Kourniaktis as execs2
24.04.Helix BioPharma Corp. Appoints New COO and Communications Director to Accelerate Growth and Deliver on its Mission Against Hard-to-Treat Cancers4
11.04.Helix BioPharma Corp (2): Helix BioPharma promotes Mehrling to CEO2
10.04.Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan1
03.04.Helix BioPharma Corp (2): Helix BioPharma hires ITG for market-making services1
03.04.Helix BioPharma Corp. Announces Engagement of Independent Trading Group to Provide Market-Making Services1
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1